Australia Flu Vaccine Facility Will Be Unique in Southern Hemisphere

Vaccine maker Seqirus announced plans to break ground early next year on a $600-million influenza vaccine manufacturing facility in Melbourne, Australia.

Capable of producing seasonal and pandemic flu vaccines, the plant will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere, says the company.

Built on a site near the city’s airport, the plant is expected to be operational in mid-2026. Plans for the facility followed an agreement with the Victoria government for onshore manufacturing to supply more than 10 years of influenza pandemic vaccines, anti-venoms and Q-Fever vaccine. The company recently completed a $140-million expansion of a facility in Holly Springs, N.C., that uses a similar technology platform.

Related Link: ENR 2020 Global Sourcebook PDF (subscription required)

Looking for quick answers on construction and engineering topics?
Try Ask ENR, our new smart AI search tool. Ask ENR →

KEYWORDS: Global Sourcebook

Bruce Buckley is a freelance writer and photographer based in the Washington, D.C., area.

Post a comment to this article

Join Groundbreaking Women in Construction (GWIC) in San Diego from June 14 to 16, 2026. This premier leadership conference brings together women across the construction industry to gain practical strategies, grow their network, and advance their careers. Learn from ENR-curated sessions, connect with trailblazing professionals, and walk away with tools that drive retention, innovation, and impact.

Live: June 23, 2026 at 2:00 pm EDT New market dynamics like competitive pressures and workforce evolutions are forcing construction companies to re-prioritize their investments. To strengthen cash flow, accelerate operations, and boost profits, learn how the focus now must be on optimizing digital transformation and financial management.